Comparative Efficacy and Safety Profile of Amlodipine 5 mg/Losartan 50 mg Fixed-Dose Combination and Amlodipine 10 mg Monotherapy in Hypertensive Patients Who Respond Poorly to Amlodipine 5 mg Monotherapy: An 8-Week, Multicenter, Randomized, Double-Blind Phase III Noninferiority Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kang, Seok-Min | - |
dc.contributor.author | Youn, Jong-Chan | - |
dc.contributor.author | Chae, Shung Chull | - |
dc.contributor.author | Park, Chang Gyu | - |
dc.contributor.author | Yang, Joo Young | - |
dc.contributor.author | Kim, Moo Hyun | - |
dc.contributor.author | Hong, Taek Jong | - |
dc.contributor.author | Kim, Cheol Ho | - |
dc.contributor.author | Kim, Jae Joong | - |
dc.contributor.author | Shin, Dong Gu | - |
dc.contributor.author | Jung, Jin Won | - |
dc.contributor.author | Yoon, Jung Han | - |
dc.contributor.author | Park, Si Hoon | - |
dc.contributor.author | Kwon, Jun | - |
dc.contributor.author | Cho, Seung Yun | - |
dc.date.accessioned | 2021-09-07T05:57:20Z | - |
dc.date.available | 2021-09-07T05:57:20Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2011-12 | - |
dc.identifier.issn | 0149-2918 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/111116 | - |
dc.description.abstract | Background: The number of hypertensive patients achieving treatment targets is not ideal with therapies that engage a single mechanism of action, and combination therapies using different mechanisms of action can increase drug efficacy in a synergistic way. Objective: This noninferiority study compared the clinical efficacy and safety profile of fixed-dose combination of amlodipine/losartan 5/50 mg and amlodipine 10 mg monotherapy in essential hypertensive patients who respond poorly to amlodipine 5 mg monotherapy. Methods: This was a double-blind, multicenter, randomized trial of hypertensive patients (N = 185) aged >=.18 years taking amlodipine 5 mg during the run-in treatment period but failed to achieve sitting diastolic blood pressure (DBP) <90 mm Hg. After randomization into the amlodipine/losartan 5/50 mg fixed-dose combination group (n = 92) and the amlodipine 10 mg monotherapy group (n = 93), treatment was maintained without dose escalation for 8 weeks. The noninferiority margin was prespecified as 4 mm Hg after 8 weeks of treatment for the difference of the average change in DBP between treatments. The primary efficacy evaluation of noninferiority was tested using a confidence interval approach with a 97.5% 1-sided lower confidence limit using the average difference in DBP measured at baseline and 8 weeks. Results: After 8 weeks, the DBP of both groups decreased from baseline by 8.9 (6.1) and 9.4 (7.5) mm Hg, respectively (difference = -0.5 [6.9] mm Hg, 95% CI: -2.5 to 1.5). Secondary end points of reductions in DBP after 4 weeks (-8.1 [6.7] vs -9.9 [7.3] mm Hg, difference = -1.8 mm Hg, 95% CI: -3.9 to 0.2) and sitting systolic blood pressure after 4 (-10.2 [11.8] vs -12.8 [10.2] mm Hg, difference = -2.6 mm Hg, 95% CI: -5.9 to 0.6) and 8 weeks (-12.2 [11.0] vs -13.4 [11.3] mm Hg, difference = -1.2 mmHg, 95% CI: -4.4 to 2.1) were comparable between the 2 treatment groups. There were 38 adverse events in 20 patients (21.7%) in the amlodipine/losartan 5/50 mg fixed-dose combination group and 31 in 24 patients (26.1%) in the amlodipine 10 mg monotherapy group; most were mild. There were 7 adverse events in 6 patients (6.5%) related to treatment in the fixed-dose combination group and 13 in 10 patients (10.9%) in the monotherapy group (P = 0.30). Conclusions: Fixed-dose combination amlodipine/losartan 5/50 mg was not inferior in terms of reductions in DBP after 8 weeks of treatment and had comparable safety profile to amlodipine 10 mg in patients who did not respond to amlodipine 5 mg monotherapy. ClinicalTrials.gov identifier: NCT00940667. (Clin Ther. 2011;33:1953-1963) (C) 2011 Elsevier HS Journals, Inc. All rights reserved. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER | - |
dc.subject | QUALITY-OF-LIFE | - |
dc.subject | BLOOD-PRESSURE | - |
dc.subject | PARALLEL-GROUP | - |
dc.subject | LOSARTAN | - |
dc.subject | TOLERABILITY | - |
dc.subject | HYDROCHLOROTHIAZIDE | - |
dc.subject | BESYLATE | - |
dc.subject | TRIAL | - |
dc.title | Comparative Efficacy and Safety Profile of Amlodipine 5 mg/Losartan 50 mg Fixed-Dose Combination and Amlodipine 10 mg Monotherapy in Hypertensive Patients Who Respond Poorly to Amlodipine 5 mg Monotherapy: An 8-Week, Multicenter, Randomized, Double-Blind Phase III Noninferiority Study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, Chang Gyu | - |
dc.identifier.doi | 10.1016/j.clinthera.2011.11.007 | - |
dc.identifier.scopusid | 2-s2.0-83455220060 | - |
dc.identifier.wosid | 000298831400009 | - |
dc.identifier.bibliographicCitation | CLINICAL THERAPEUTICS, v.33, no.12, pp.1953 - 1963 | - |
dc.relation.isPartOf | CLINICAL THERAPEUTICS | - |
dc.citation.title | CLINICAL THERAPEUTICS | - |
dc.citation.volume | 33 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 1953 | - |
dc.citation.endPage | 1963 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | QUALITY-OF-LIFE | - |
dc.subject.keywordPlus | BLOOD-PRESSURE | - |
dc.subject.keywordPlus | PARALLEL-GROUP | - |
dc.subject.keywordPlus | LOSARTAN | - |
dc.subject.keywordPlus | TOLERABILITY | - |
dc.subject.keywordPlus | HYDROCHLOROTHIAZIDE | - |
dc.subject.keywordPlus | BESYLATE | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordAuthor | amlodipine | - |
dc.subject.keywordAuthor | hypertension | - |
dc.subject.keywordAuthor | losartan | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.